Drugs / KER-012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05975905 | Oct 2023 → Mar 2025 | pulmonary arterial hypertension | Keros Therapeutics, Inc. | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07202000 Comparator | Jun 2026 → Jul 2027 expected | diastolic heart failure | Massachusetts General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KER-012 | “Activin ligand-trap biological therapy (KER-012) subcutaneously (SC) 1.5mg/kg every 4 weeks X 3” NCT07202000 ↗ |
| Action | Inhibit | “activin inhibition” NCT07202000 ↗ |
| Modality | Protein / enzyme biologic | “activin ligand-trap biological therapy” NCT07202000 ↗ |
| Route | Subcutaneous | “subcutaneously (SC)” NCT05975905 ↗ |